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a b s t r a c t 
Parkinson’s disease (PD) is a chronic debilitating disease affecting approximately 1% of the 
population over the age of 60. The severity of PD is correlated to the degree of dopaminer- 
gic neuronal loss. Apomorphine has a similar chemical structure as the neurotransmitter 
dopamine and has been used for the treatment of advanced PD patients. In PD patients, 
apomorphine is normally administered subcutaneously with frequent injections because 
of the compound’s extensive hepatic first-pass metabolism. There is, hence, a large unmet 
need for alternative administrative routes for apomorphine to improve patient compliance. 
The present review focuses on the research and development of alternative delivery of apo- 
morphine, aiming to highlight the potential of non-invasive apomorphine therapy in PD, 
such as sublingual delivery and transdermal delivery. 
© 2017 Shenyang Pharmaceutical University. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
 
 
 
 
 
 
 
 
 
 1. Introduction 
The earliest reported synthesis of apomorphine was described
by Arppe in 1845 and later by Matthiesen and Wright in 1869,
which involved reacting morphine with hydrochloric acid or
sulfuric acid, respectively, to obtain apomorphine [1] . Apomor-Abbreviations: PD, Parkinson’s disease; SEDDS, Self-emulsifying dru
acid)-cysteine-2-mercaptonicotinic acid. 
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1818-0876/© 2017 Shenyang Pharmaceutical University. Published by El
license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) phine found its early use in veterinary therapeutics to treat is-
sues associated with farmyard animal behavior. By 1874, it was
known that apomorphine had effects on the central nervous
system along with emetic effects [1,2] . In human medical use,
the compound was recommended as an emetic, sedative, as
well as a treatment for narcotic and alcohol addiction [3] . Weilg delivery system; L-dopa, Levodopa; PAA-cys-2MNA, poly(acrylic 
nhagen, Universitetsparken 2, Copenhagen 2100, Denmark. 
rsity. 
sevier B.V. This is an open access article under the CC BY-NC-ND 
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rn 1884 suggested apomorphine for its potential use in treat- 
ng Parkinson’s disease (PD) [4,5] . Schwab and coworkers and 
otzias confirmed Weil’s suggestion, as they found a signifi- 
ant decrease in tremors and rigidity associated with PD in hu- 
ans [6–9] . In today’s medical treatment, subcutaneous apo- 
orphine is used for the treatment of advanced PD in patients 
ndergoing motor disabilities that do not respond to other 
D treatments. There is a large unmet need for alternative 
pomorphine delivery systems, as this treatment is provided 
y multiple subcutaneous injections daily. This review covers 
he importance of apomorphine in PD management and em- 
hasizes the challenges with apomorphine therapy for PD pa- 
ients. The present review also aims at highlighting some key 
esearch developments in the area of non-invasive delivery of 
pomorphine. 
. Physicochemical properties of 
pomorphine 
pomorphine (6-methyl-6 αβ-noraporphine- 10,11-diol) be- 
ongs to the class of β-phenylethylamines sharing structural 
imilarities to the neurotransmitter, dopamine, both having 
 catechol moiety ( Fig. 1 ). Apomorphine is a chiral molecule 
MW: 267.32 Da). The R-form is a dopamine agonist, while the 
-form of the molecule may possess anti-dopaminergic activ- 
ty [10,11] . ig. 1 – Chemical structures of R-(-)-apomorphine and 
opamine. 
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Table 1 – Currently marketed apomorphine formulations. 
Product name Company 
Apometic ® [15] Forum Animal Health 
Uprima®, Ixense®, Spontane ®, 
TAK 251 [16] 
Pentech Pharmaceuticals Inc. 
(originator and developer); 
Takeda Pharmaceutical 
Company Ltd. (developer) 
APO-go, Apokinon, Apokyn, 
Apomine, Britaject, KW-6500, 
Li Ke Ji, MOVAPO ® [17] 
Britannia Pharmaceuticals Ltd. 
(originator and developer); 
Kyowa Hakko Kirin Co. Ltd. and 
US WorldMeds (developer) Apomorphine is water-soluble with an intermediate 
ipophilicity represented by a log P of 2.0 [12] . The compound
as two pK a values, at 7.0 and 8.9 [13] , and it is generally avail-
ble as the hydrochloride salt. The hydrophilic character of 
pomorphine allows it to be solubilized and therefore, formu- 
ated as an aqueous solution. Moreover, it is readily mixed in 
issue fluids and can be absorbed into the systemic circulation 
nd subsequently cross the lipophilic blood-brain barrier [14] .
. Therapeutic uses of apomorphine 
pomorphine has been used in the treatment of several ail- 
ents. Table 1 illustrates the various apomorphine products 
urrently available on the market. In veterinary practices, apo- 
orphine is utilized as an emetic agent, which induces vom- 
ting as a part of managing poisoning in dogs and other an- 
mals. Apomorphine acts on the dopamine receptors in the 
chemoreceptor trigger zone’ in the area postrema of the 
edulla oblongata as well as the receptor cerebrospinal fluid 
ide [2] . 
One of the prescribed uses of apomorphine is its appli- 
ation in male erectile dysfunction. Apomorphine has been 
emonstrated to be an effective erectogenic agent by stimu- 
ating the postsynaptic dopamine receptors in the hypothala- 
us [18,19] . A sublingual apomorphine formulation has been 
eported to have 18–19 min as an onset time of erection requir- 
ng very low ( < 1.5 ng/dl) apomorphine concentrations at the 
ite of action [19] . Apomorphine therapy in improving erectile 
esponse can be considered as a valuable alternative to other 
reatments for erectile dysfunction. 
The predominant therapeutic use of apomorphine is its use 
n PD. PD is a debilitating disease which is characterized by 
hronic neurodegeneration of the striatal region of the brain 
ausing a deficiency of neurotransmitter dopamine [20,21] . Re- 
lacing the loss of dopamine by using dopamine agonist is the 
hoice of treatment for many PD patients. Apomorphine, a po- 
ent dopamine agonist, is commonly used as rescue therapy 
n subcutaneous formulations in advanced stage PD patients.
pomorphine and its role in PD are discussed in detail in the 
ollowing sections. 
Apomorphine has demonstrated its therapeutic effects in 
reating Alzheimer’s disease. Alzheimer’s disease is charac- 
erized by a loss of memory and cognitive functions, which Dosage form and route of 
administration 
Indication 
Solution for subcutaneous 
injection 
Emesis for veterinary practice 
Sublingual tablet Erectile dysfunction 
Solution for subcutaneous 
injection 
Parkinson’s disease 
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 is attributed to hyperphosphorylated tau protein and amy-
loid β-protein [22] . Apomorphine increases amyloid β-protein
degradation and protects neuronal cells from oxidative stress.
Therefore, it restores memory function and improves pathol-
ogy traits of Alzheimer’s disease assessed in a mice model [23] .
More such studies in the future might establish apomorphine
as a novel therapeutic agent in treating Alzheimer’s disease. 
4. Parkinson’s disease and its treatment 
PD is one of the most common chronic neurodegenerative
diseases affecting about 1% of the population over the age
of 60 [20] . As aforementioned, the dopamine-secreting neu-
rons in the nigrostriatal region of brain undergoes a progres-
sive degeneration leading to a depletion of dopamine in pa-
tients with PD [21] . The low levels of dopamine in the stria-
tum have several implications on motor abilities, such as rest
tremor, bradykinesia (slowness of movement), rigidity, postu-
ral instability, and falls. The non-motor complications involv-
ing the non-dopaminergic brain regions, such as neuropsychi-
atric and autonomic disturbances, cognitive impairment, etc.
generally surface as the disease progresses [20] . 
PD is yet incurable; however, various symptomatic ther-
apies are available to improve the quality of life as well as
longevity for the PD patients. The severity of PD correlates to
the degree of dopaminergic neuronal loss. In order to under-
stand the need for apomorphine in the treatment of PD, one
must understand the usage of levodopa (L-dopa) in managing
PD. L-dopa, a precursor of dopamine, is the most efficacious
oral drug available for alleviating symptoms of early stages
of PD. L-dopa (dihydroxyphenylalanine) is also an endoge-
nous intermediate in the synthesis of catecholamine neuro-
transmitters. In contrast to dopamine, L-dopa can be absorbed
across the blood-brain barrier and converted to dopamine in
the striatum [24] . 
In early stages of PD, it has been shown that L-dopa eases
several symptoms, such as freezing, somnolence, edema, and
hallucinations [25] . However, long-term therapy with L-dopa
is limited due to a decrease in its efficacy. The prolonged
use of L-dopa also causes appearance of adverse effects of
dopaminergic motor functions especially dyskinesia (impair-
ment in voluntary movements) [26,27] and wearing off (‘on–
off’ phenomenon) [28] . The “on–off” phenomenon in PD refers
to a switch between mobility and immobility, which occurs
as a worsening of motor function or, much less commonly,
as sudden and unpredictable motor fluctuations as the dis-
ease progresses. As a result, dopamine receptor agonists are
used alone or in combination with L-dopa to delay the on-
set of motor complications. Dopamine agonists can also be
effective in early PD, especially in cases where the disease oc-
curs in “younger” patients, where dyskinesia is a greater risk
[29,30] . Dopamine receptor agonists stimulate the post- and
presynaptic dopaminergic receptors [31] . 
4.1. Apomorphine therapy 
More than 50% of Parkinson’s disease patients develop ‘on–
off phenomenon’ with a prolonged L-dopa use of greater than
5 years, which warrants the use of dopamine agonists suchas apomorphine [32,33] . Apomorphine, a mixed D1 and D2
dopamine agonist, predominantly finds its use as a rescue
medicine to treat the ‘off’ period in L-dopa therapy. The D1
potency by apomorphine is exhibited by the catechol moiety
[34] , while the bulky aromatic part of the molecule may con-
tribute to the affinity toward D2 receptors [35] . The potency of
apomorphine and L-dopa has been shown to be comparable to
each other [36–38] . Unlike oral L-dopa therapy, apomorphine is
administered subcutaneous in the abdomen region as an in-
termittent injection or by continuous infusion using an infu-
sion pump [39] . The avoidance of dyskinesia is a major advan-
tage of apomorphine treatment over L-dopa therapy. However,
apomorphine administration has several disadvantages such
as nausea and vomiting; thus, requiring anti-emetics, which
are often co-dosed (such as, domperidone) [40] . Additionally,
subcutaneous apomorphine therapy may give rise to prob-
lems with patient compliance associated with needle phobia
or local pain due to irritation and inflammation followed by a
formation of subcutaneous nodules [41–43] . 
4.2. Challenges with apomorphine therapy 
Although apomorphine has medical applications, its inherent
instability poses a complication in clinical practice. Oxidation
of apomorphine is one of the pharmaceutical challenges when
it is formulated as an aqueous solution. Apomorphine spon-
taneously undergoes oxidative decomposition in aqueous so-
lution to yield a bluish-green color in the presence of light and
air [44,45] . The catechol group of the apomorphine molecule
is highly susceptible to oxidation leading to the formation of a
quinone [44,46,47] . The decomposition of apomorphine is de-
pendent on its concentration as well as the pH and tempera-
ture of the solution [44,48] . The chemical half-life of apomor-
phine is reported to be 39 min under conditions similar to that
of plasma (at 37 °C and pH 7.4) [48] . The additions of antioxi-
dants, chelating agents, or alteration of the formulation pH are
some of the approaches reported in the literature to prevent
the autoxidation of the molecule [44,49,50] . 
Another major challenge associated with apomorphine
is the deactivation upon metabolism of apomorphine after
administration. The in vivo conversion from the R-form of
apomorphine, which is pharmacologically active, to the S-
form lowers the pharmacological activity of the molecule
[51] . Additionally, apomorphine is metabolized via numer-
ous enzymatic pathways predominantly in the liver, but also
in the brain and tissue fluids [52] . Some of the metabolic
pathways include sulfation, glucuronidation, and catechol-O-
methyltransferase [51,53–56] . Moreover, a large pharmacoki-
netic variability is reported between PD patients after subcuta-
neous administration of apomorphine [53] . This inter-subject
variability may be caused by the interactions of the drug and
its various metabolites with plasma and tissue, which compli-
cates the clinical dose setting [44] . 
The clinical utility of apomorphine upon oral administra-
tion is highly limited due to hepatic first-pass metabolism
[57] . The oral absorption of apomorphine in rats with surgi-
cal portacaval venous anastomosis or shunting was reported
to be similar to the absorption after subcutaneous applica-
tion. In contrast, the sham operated rats with intact portal-
hepatic venous circulation had undetectable tissue concentra-
510 Asian Journal of Pharmaceutical Sciences 13 (2018) 507–517 
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oion of apomorphine [52] . This suggested that apomorphine 
as well absorbed when given orally, but underwent an ex- 
ensive metabolism in the liver. The metabolic constraints can 
ccount for a poor oral bioavailability of less than 4% in PD pa- 
ients [57] . 
Due to a high extent of apomorphine metabolism, a plasma 
alf-life of about 32 min is reported after subcutaneous ad- 
inistration [48,58] . This short plasma half-life necessitates 
 higher frequency of injections to maintain a concentration 
f apomorphine in the blood and subsequently, in the brain.
 continuous subcutaneous infusion may be used if apomor- 
hine subcutaneous injections exceed 7–9 times daily [40] . As 
entioned previously, this causes inconvenience to patients 
ith PD and often leads to patient non-compliance. Addition- 
lly, self-injection might prove difficult for patient in late stage 
D during ‘off’ periods due to impairment of motor functions 
59] . 
. Drug delivery approaches for apomorphine 
here is a high medical need for improving apomorphine 
ioavailability via various approaches and/or administrative 
outes to improve patient convenience and compliance. The 
ections below highlight the developments in non-invasive 
elivery of apomorphine, which are setting a pathway for the 
uture of apomorphine therapy in PD. 
.1. Chemical modification: Prodrug approach 
ynthesizing prodrugs can be a method to improve physico- 
hemical, biopharmaceutical and/or pharmacokinetic proper- 
ies of an active compound. Prodrugs are derivatives of drug 
ompounds which undergo enzymatic or chemical biotrans- 
ormation to yield the pharmacologically active parent drug 
n vivo , which can exert its therapeutic action. One promi- 
ent site for derivatization for apomorphine is the catechol 
oiety in the molecule to synthesis diesters of apomor- 
hine. Fig. 2 illustrates the general apomorphine esterifica- 
ion reaction yielding apomorphine diesters. Early literature 
n derivatization of apomorphine molecule was reported by 
orgman et al., where diacetyl, dipropionyl, diisobutyryl, dip- 
valoyl , and dibenzoyl esters of apomorphine were synthe- 
ized [60,61] . Stereotyped gnawing behavior and unilateral ro- 
ation were investigated upon intraperitoneal administration 
o rats. The duration of action of the diesters was significantly Fig. 2 – General scheme of esterification of R-(-)-ancreased compared to that of free apomorphine. Apart from 
ltering the pharmacokinetics, the advantage of esterification 
n the catechol moiety is that it inhibits oxidation of hydroxyl 
roups [62] , thereby enabling the development of more chem- 
cally stable formulations. 
Although the first reported apomorphine esters were ad- 
inistered via an invasive intraperitoneal route, there are 
everal studies of apomorphine esters which explored non- 
nvasive routes of administration, such as the transdermal 
nd oral route. Liu et al. investigated the transdermal deliv- 
ry of two diesters of apomorphine: diacetyl and diisobutyryl 
pomorphine [12] . The diester prodrugs were more lipophilic 
han apomorphine and were determined as substrates to the 
sterases present in esterase medium, nude mouse skin ho- 
ogenate, and human plasma. Apomorphine and its diester 
rodrugs formulated in lipid emulsions were investigated for 
heir permeation across the skin of nude mouse (area of 
.785 cm 2 ) using Franz diffusion cell. Diacetyl and diisobutyryl 
pomorphine yielded 11 and 3 folds higher fluxes, respec- 
ively, when compared to apomorphine. The results indicated 
 promising transdermal delivery of apomorphine by incorpo- 
ating bioreversible lipophilic prodrugs in lipid-based carrier. 
Apomorphine diester prodrugs have also been investigated 
or their oral delivery. Borkar and colleagues investigated the 
ossibility of developing oral apomorphine formulations by 
ynthesizing lipophilic derivatives of the molecule and incor- 
orating them into lipid formulations [63] . The objective of uti- 
izing lipophilic derivatives in lipid carrier was to stimulate the 
ymphatic drug transport, which will be further discussed in 
ection 5.2.1 . Lipidifying apomorphine via prodrug was suc- 
essfully demonstrated by obtaining highly lipophilic diesters: 
ilauroyl and dipalmitoyl apomorphine, which were 6.5 and 
.5 times more lipophilic (based on the logarithm of partition 
oefficient (log P ) value), respectively, than their parent drug.
his high lipophilicity of the diesters allowed them to be dis- 
olved in lipid vehicles required to obtain lipid-based formu- 
ations. Additionally, the apomorphine diesters exhibited dif- 
erences in their enzymatic degradation when incubated in 
iorelevant medium containing pancreatic extract. About 28% 
ipalmitoyl diester remained intact, while only 4% dilauroyl 
pomorphine was left undegraded after 5 min of incubation.
t was suggested that the longer alkyl chain of dipalmitoyl 
pomorphine (C16) might have exhibited higher steric hin- 
rance during enzymatic cleavage of the ester bond than di- 
auroyl apomorphine (C12). The need for enzymatic hydrolysis 
f the apomorphine diesters before initiation of the therapeu- pomorphine to yield apomorphine diesters. 
Asian Journal of Pharmaceutical Sciences 13 (2018) 507–517 511 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 tic action was also demonstrated by the presence of a lag time
(about 30 min) in a 6-hydroxydopamine-induced rotational rat
model [64] . 
Another study used R-(–)-11-O-valeryl-N-n-
propylnoraporphine HCl as an oral apomorphine derivative
to evaluate its motor effects on 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-treated marmosets [65] . The fast onset
and prolonged duration of the therapeutic effects meant a
reversal of motor deficits and improvement of dyskinesia
in the PD marmoset model. These studies demonstrated
that the various parameters in the apomorphine prodrug
synthesis, such as chain length, branching and different types
of substituents can be modified to alter the physicochemical
and biopharmaceutical properties for the drug molecule. 
5.2. Formulation and non-invasive drug delivery 
strategies 
Various delivery strategies have been investigated to adminis-
ter apomorphine using an approach which utilizes alternative
routes besides the subcutaneous route. This section focuses
on the non-invasive apomorphine delivery approaches inves-
tigated in previous studies. 
5.2.1. Oral delivery 
Oral delivery of apomorphine suffers from a very poor oral
bioavailability (less than 4%) because of extensive hepatic
first-pass metabolism [57] . Early in vivo investigations of apo-
morphine administered orally revealed that there was relief in
PD symptoms at high doses of apomorphine (up to 500 mg), al-
though azotemia was observed [8] . Tsai and coworkers investi-
gated the possibility of developing an oral delivery of apomor-
phine by incorporating it into solid lipid nanoparticles [66] .
Glyceryl monostearate and polyethylene glycol monostearate
were individually used as emulsifiers in the lipid nanoparti-
cles composed of a lipid phase (tripalmitin and hydrogenated
soybean phosphatidylcholine) and an aqueous phase (Pluron-
ic® F68 and L-ascorbic acid). The relative oral bioavailabil-
ity in rats increased to 25%–28% after administration of apo-
morphine in solid lipid nanoparticles, while it was a mere 2%
for the apomorphine aqueous solution (control). An improved
therapeutic efficacy was demonstrated by a 5–6 fold increase
in rotation scores in 6-hydroxydopamine-lesioned rats from
the groups receiving the solid lipid nanoparticle formulations
compared to the control group. 
One way to avoid the hepatic first-pass metabolism upon
oral administration is to stimulate drug transport via the lym-
phatics [67–69] . Generally, compounds with a log P value > 5
and a triglyceride solubility > 50 mg/g have a larger poten-
tial to be transported lymphatically after oral administration,
but exceptions also exist [69,70] . Apomorphine has a log P
value of 2.0 [12] , so in order to have any potential for lym-
phatic transport the lipophilicity of the molecule needs to
be increased. Borkar and coworkers lipidified apomorphine
to synthesize prodrugs and incorporated these prodrugs in
self-emulsifying drug delivery systems (SEDDS) [63] . Various
SEDDS formulation compositions were used with excipients
like triglycerides (medium chain, soybean oil, or castor oil),
Kolliphor® RH40 (surfactant), Maisine TM 35–1 (co-surfactant)and ethanol (co-solvent). The incorporation of the diester pro-
drugs in SEDDS kept the prodrugs as intact molecules pre-
venting their enzymatic hydrolysis in the presence of pan-
creatic lipase and other esterases when incubated in simu-
lated intestinal fluids. This was further carried out to assess
the prodrug affinity toward chylomicrons, which are the pre-
dominant class of lipoproteins mediating the intestinal lym-
phatic drug transport [71] . Even though the diester prodrugs
had a low affinity toward chylomicrons, a pharmacokinetic
and pharmacodynamic study was conducted in order to as-
sess the drug absorption process in a dynamic in vivo sys-
tem. Various lipid-based formulations such as, oil-in-water,
water-in-oil emulsions, SEDDS, pure co-surfactant and pure
oil loaded with apomorphine prodrug were assessed in rats
[72] . Borkar and coworkers reported that apomorphine loaded
in soybean oil had a long t max , which was possibly caused by
an increase in gastric emptying time and a slower triglyceride
digestion, subsequently a slower drug release. Although the
relative bioavailabilites from the lipid-based vehicles inves-
tigated were in the low end, a pharmacodynamic study was
carried out in 6-hydroxydopamine-lesioned rats to evaluate
if the obtained plasma concentrations could lead to a ther-
apeutic effect in the brain [64] . SEDDS formulations gave a
sustained behavior response for 6 h while, oil-in-water emul-
sion loaded with apomorphine diester prodrug yielded a re-
sponse which lasted for about 2.5 h after administration. It
was demonstrated that a sustained oral delivery of apomor-
phine prodrug using lipid-based formulations was feasible
and thereby, could hold a potential in reducing or eliminating
the frequent subcutaneous injections. 
5.2.2. Sublingual delivery 
Sublingual apomorphine delivery is beneficial for several rea-
sons; the predominant reason being the avoidance of hep-
atic first-pass metabolism and an ease in administration with
rapid onset of action. Lees et al. conducted a study with sub-
lingual apomorphine in nine patients with idiopathic PD with
12 years as an average duration of the disease [73] . The sublin-
gual apomorphine yielded a comparable therapeutic efficacy
when compared to the efficacy observed after subcutaneous
apomorphine administration. There was a latency observed
in the pharmacological effect after sublingual dose, which was
suggested to be induced by the time required for tablet disso-
lution, which was 33 min on average [73] . Similarly, an onset
time of 30 min was reported by Durif et al. after sublingual ad-
ministration of a apomorphine tablet compared to 14 min af-
ter subcutaneous injection in a patient study including 8 pa-
tients [74] . The therapeutic effects after sublingual adminis-
tration were also noted to be sustained for a longer period of
time relative to the subcutaneous administration. 
A formulation currently being investigated and devel-
oped is apomorphine sublingual film strip formulation (APL-
130277) [75,76] . It is a dissolvable thin-film strip formulated
with apomorphine as a laminated bilayer to prevent mucosal
irritation ( Fig. 3 ). The first layer (light blue layer in Fig. 3 ) is a
cellulose ether-based film containing apomorphine, stabiliz-
ers and plasticizers, while the second layer (dark blue layer in
Fig. 3 ) is composed of a similar cellulose film base consisting of
pH modifier, flavoring agent and a permeation enhancer [77] . 
512 Asian Journal of Pharmaceutical Sciences 13 (2018) 507–517 
Fig. 3 – A graphical representation of APL-130277 bilayer sublingual strip formulation. Modified and reprinted with 
permission from Cynapsus Therapeutics, Inc. © Cynapsus Therapeutics, Inc., Toronto, Ontario, Canada. 
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wIn a study performed with 19 patients, 15 patients re- 
ponded and had a quick conversion from ‘off” state to ‘on’ 
tate within 15–30 min. Sixty percent of the responders had 
 response duration which lasted for at least 60 min [75] . A 
tudy conducted in Syrian golden hamsters revealed no irri- 
ation of the buccal mucosa after three times daily applica- 
ions of APL-130277 for 28 consecutive days [77] . A phase III 
linical trial is currently in the pipeline to investigate the effi- 
acy, safety and tolerability of APL-130277 ( ClinicalTrials.gov ,
dentifier: NCT02469090). APL-130277 could provide for a ther- 
peutically effective and patient compliant way to administer 
pomorphine during ‘off’ episodes in PD patients. 
.2.3. Nasal or inhalation delivery 
rug delivery through the nasal cavity have been extensively 
xplored for its intrinsic advantages, such as ease of appli- 
ation, circumvention of the hepatic first-pass metabolism 
nd degradation in the gastrointestinal tract enabling a re- 
uction in drug dose compared to the oral dose. The consid- 
rably larger absorption area in the nasal cavity, due to the 
resence microvilli along with rather extensive vasculariza- 
ion, often results in quick drug absorption and a fast onset of 
ction upon nasal administration [78] . 
One of the early investigations for administering apomor- 
hine via the nasal route was conducted by Kapoor et al [79] .
he onset of motor response was on average reported to occur 
.9 min after administration, lasting for an average of 44 min.
am et al. studied apomorphine pharmacokinetics after nasal 
nd subcutaneous administration [58] . The nasal absorption 
alf-life was reported to be 8.6 ±2.6 min. This suggested that 
pomorphine was absorbed rapidly, which was similar to sub- 
utaneous administration where the absorption half-life was 
.8 ±1.9 min. Therefore, nasal administration seems to be a 
romising route of administration as a ‘rescue’ therapy of apo- 
orphine. 
The research stemming out from the initial investigations 
n nasal absorption of apomorphine focused on increasing 
he residence time of the drug loaded formulation on the 
asal mucosa. For instance, Ugwoke and colleagues prepared ormulations of freeze-dried powder containing apomorphine 
sing excipients such as, carboxymethylcellulose, degradable 
tarch microspheres and lactose [80] . An in vitro drug release 
tudy was conducted in phosphate buffer (pH 6.0) and an in 
ivo pharmacokinetic study was performed, where the drug 
ontaining powder was insufflated in the nasal cavity of New 
ealand white rabbits. The in vitro drug release and in vivo 
bsorption profile of the carboxymethylcellulose formulation 
emonstrated a sustained release and absorption of apomor- 
hine, where a 15% (w/w) drug loaded formulation had 50% 
f C max maintained for 70 min compared to degradable starch 
icrospheres and lactose formulations, which were 35 min 
r less. In another study, Ugwoke et al. reported further sus- 
ained release of apomorphine by incorporation of mucoad- 
esive polymers (Carbopol 971P and polycarbophil) into the 
owder formulations containing apomorphine [81] . Apomor- 
hine was detected in the plasma of the rabbits for as long as
–8 h after administration of the mucoadhesive powder for- 
ulations. The nasal drug clearance using radiolabeling was 
ssessed, where the mucoadhesive polymers in combination 
ith apomorphine increased their residence time within the 
asal cavity enabling a sustained drug release and absorption 
82] . Ugwoke et al. also tried to combine excipients for imme- 
iate drug release (lactose powder) with sustained release for- 
ulation (Carbopol matrix) to increase the initial plasma drug 
oncentration, which was, however, an unsuccessful attempt 
83] . 
Recently, the use of thiomers as a mucoadhesive bio- 
aterial in apomorphine formulation has been explored as 
n effort to prolong the residence time of the formulation 
n the nasal cavity [84] . Various poly(acrylic acid) thiomers 
ere synthesized. These thiomers were pre-activated to yield 
oly(acrylic acid)-cysteine-2-mercaptonicotinic acid (PAA- 
ys-2MNA) with varying degrees of pre-activation, which pro- 
ected the thiomer from oxidation and thus, retained its mu- 
oadhesive properties. High degree of pre-activation of PAA- 
ys-2MNA, as an excipient in aqueous solution of apomor- 
hine, yielded a higher absolute bioavailability of about 27% 
hen compared to the oral and intranasally administered 
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 apomorphine solution without the thiomer. Moreover, these
thiomers have been reported to be non-toxic toward Caco-2
cells [85] thereby, potentially possessing low risk of local toxi-
city on the nasal mucosa. 
In a phase II, placebo-controlled, double blind clinical
study, Grosset and coworkers investigated the therapeutic ef-
ficacy of inhaled dry powder of apomorphine (VR040) via an
inhalation device, i.e. pulmonary delivery [86] . Apomorphine
was absorbed very quickly (2–7 min) leading to a rapid trans-
formation (mean 10 min) to the ‘on’ state from ‘off’ state.
The incidences of adverse effects were not different between
VR040 and the placebo group, suggesting no compromise in
safety. The quick onset of action and the ease of administra-
tion make nasal apomorphine delivery a viable option used
for ‘rescue’ therapy. 
5.2.4. Transdermal delivery 
Transdermal drug delivery possesses similar benefits as nasal
delivery, which favors apomorphine absorption. Liu et al. in-
vestigated the potential of apomorphine transdermal delivery
by loading apomorphine free base, its hydrochloride salt, and
two of its diesters (diacetyl and diisobutyryl apomorphine)
into lipid emulsions [12] . Prior to emulsification, the com-
pounds were dissolved in the lipid phase consisting of 12%
(w/v) mineral oil and 0.3% (w/v) Myverol TM , while the aque-
ous phase contained water and 2.5% (w/v) Pluronic® F68. As
an exception, apomorphine HCl was dissolved in the aqueous
phase. The flux across nude mouse skin (area of 0.785 cm 2 )
of diisobutyryl apomorphine was determined and found to be
lower than that of diacetyl apomorphine when the prodrug
was incorporated into lipid emulsions. It was suggested that
the higher log P value of diisobutyryl apomorphine retained
the compound in the oil phase retarding its release from the
formulation. This characteristic may potentially be utilized to
obtain a prolonged release and absorption of the apomorphine
diester. However, the unpleasant oily or sticky feeling on the
skin from the lipid vehicle might limit the pharmaceutical ap-
plicability. 
Peira et al. studied absorption via the transdermal route us-
ing apomorphine loaded microemulsions [87] . The formula-
tions were composed of apomorphine HCl, octanoic acid, 1,2
propanediol, sodium hexanoate, sodium glycocholate (or tau-Fig. 4 – A graphical representation of an iontophrocholate) dissolved in water (pH 6.0), Epikuron 200 as surfac-
tant and an oil phase of isopropylmyristate–decanol. In ad-
dition to the formulation vehicle, ion pairs of apomorphine–
octanoic acid were prepared to increase lipophilicity of the
drug and to enhance the transdermal permeation across hair-
less mouse skin with a diffusible area of 1.7 cm 2 . As a follow up
study, Priano et al. conducted an in vivo study using such apo-
morphine microemulsions on twenty-one idiopathic PD pa-
tients, who exhibited long term L-dopa syndrome or a lack
of complete reduction of ‘off’ period [88] . The apomorphine
microemulsion was applied as a 1 mm thick layer creating a
reservoir on to 100 cm 2 skin area over the chest surrounded
by 1 mm thick biocompatible foam tapes and enclosed by a
polyester-based and an occlusive membrane. Apomorphine
microemulsions applied with oral administration of L-dopa
demonstrated a rapid increase in apomorphine plasma con-
centration to obtain therapeutic levels and a prolonged ab-
sorption with a t max of 5.1 h compared to t max of 20 min after
subcutaneous administration. 
One of the novel routes for controlled delivery of apo-
morphine is transdermal iontophoresis. The salient feature
and a major advantage of transdermal iontophoresis is that
it possesses the potential to deliver apomorphine as per
the need, not only by measuring patient’s pharmacokinet-
ics, but by the possibility of measuring their pharmacody-
namic output. Fig. 4 illustrates a representation of a typi-
cal iontophoretic patch. Li and coworkers evaluated a ion-
tophoretic patch designed with a anodal compartment filled
with R-apomorphine solution (sodium chloride, ascorbic acid
and citrate buffer, pH 5.0) and the cathodal compartment
filled with a phosphate buffered saline solution (pH 7.4) [90] .
The delivery of apomorphine can be regulated by the cur-
rent density in the device. In this study, the current density
was 250 μA/cm 2 with a skin contact patch area of 20 cm 2 .
This study aimed at investigating the in vivo effects of the
transdermal iontophoretic patch with and without a sur-
factant pre-treatment between cohorts of advanced PD pa-
tients. The patients treated with pre-treatment showed a sig-
nificantly higher bioavailability (13%) and steady state flux
(98.3 ± 12.1 nmol/cm 2 h) from the non-pre-treated group with
10% bioavailability and 75.3 ± 6.6 nmol/cm 2 h steady state in-
put rate. Similarly, Li et al. explored different surfactant for-oretic patch. Modified from Green, 1996 [89] . 
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rulation pre-treatment to enhance the apomorphine trans- 
ermal iontophoretic delivery across skin area of 0.64 cm 2 
ith an 500 μA/cm 2 current density [91] . In this study, Li 
nd colleagues prepared various compositions of surfac- 
ant formulations consisting of laureth-3 oxyethylene ether,
aureth-7 oxyethylene ether, and cholesterol sulphate and 
emonstrated a 2-fold increase in the steady state flux to 
81.5 ±22.6 nmol/cm 2 h relative to the group without any sur- 
actant pre-treatment. These studies indicated a safe alterna- 
ive delivery methodology yielding only minor and temporary 
ocal skin irritation [90,91] . This patient customized apomor- 
hine delivery system with iontophoresis could hold a great 
otential for optimizing the drug dose of apomorphine. 
.2.5. Rectal delivery 
n a study conducted in three patients, apomorphine was 
dministered with a rectal enema solution at the beginning 
f the ‘off’ period [92] . The observed clinical efficacy in the 
atients was comparable to that after subcutaneous or in- 
ranasal administration. Thereby, the administration of rectal 
nema showed its potential for a quick relief from ‘off’ state 
ymptoms. Huges et al. studied rectal apomorphine adminis- 
ration using suppositories [93] . Five out of eleven patients had 
 full reversal from the ‘off’ state and had a mean latency of re- 
ponse of 32 min. The plasma levels of apomorphine after rec- 
al administration were sustained, but became lower than that 
fter sublingual and subcutaneous administration, and exhib- 
ted higher inter-patient variability. The slower onset of action 
ight prove this route applicable as an adjunct to subcuta- 
eous administration, for patients requiring frequent subcu- 
aneous injections, or patients having disabilities at night. Van 
aar and colleagues performed a comparative study with a 
ectal apomorphine solution, a gelatin and a Witepsol®-H15 
uppository [94] . The group receiving Witepsol® suppository 
xhibited a longer t max (127.5 ±7.5 min) and a longer duration 
f action than the group receiving the rectal solution (t max 
6.0 ± 2.5 min and duration of action 50.0 ± 13.1 min). A high 
nter-patient variability in the bioavailabilities was noted, the 
roup of patients receiving gelatin suppository demonstrated 
 bioavailability of 40.2 ±22.9%, which was higher than the 
roup receiving Witepsol® (18.9 ±8.1%). Witepsol® supposi- 
ory base can prove to be useful in achieving sustained re- 
ease of apomorphine; however, due to the inconvenience of 
ectal administration, it would probably only be the admin- 
stration route chosen when alternative routes have adverse 
vents making them non-feasible. 
. Efforts by pharmaceutical industry on 
evelopment of apomorphine delivery 
s mentioned in the sections above, a number of formula- 
ions containing apomorphine have already been introduced 
o the market, such as the solution for subcutaneous injec- 
ion and tablet for sublingual administration for PD and erec- 
ile dysfunction, respectively. While these formulations cover 
 medical need, the discussions above have clarified some of 
he disadvantages dealing with poor bioavailability and phar- 
acokinetics in particular with the non-invasive PD treat- 
ent with apomorphine. Several companies, including Vec- ura Group PLC, Amarin Pharma Inc., and Britannia Pharma- 
euticals Ltd. have worked or are still working on drug delivery 
olutions that may potentially overcome some of these disad- 
antages. 
The different delivery attempts of apomorphine for the 
se in PD including non-invasive sublingual, intranasal, and 
ulmonary deliveries have continued into clinical trials, but 
topped before commercialization for various reasons. Many 
f the companies that have been active in the field no longer 
ention apomorphine on their homepages and all seem 
losed, but one program by Cynapsus Therapeutics Inc. that 
as a sublingual version of apomorphine in clinical phase III,
s discussed in Section 5.2.2 . While this is naturally a disap- 
ointment to the patients suffering from PD, that no alterna- 
ive delivery options beyond subcutaneous injection seem to 
e available within the near future, there is still reason to be- 
ieve that all stones have not been turned yet. However, non- 
nvasive drug delivery of apomorphine is certainly a hard chal- 
enge to solve from a drug delivery perspective. 
. Conclusion 
he challenges with non-invasive apomorphine therapy range 
rom drug stabilities to absorption barriers. The chemical sta- 
ility of apomorphine could be improved by addition of an- 
ioxidants and chelating agents, or prodrug strategy, whereas 
he enzymatic stability of apomorphine should be considered 
n connection with the alternative formulation choice or de- 
ivery route. Combining prodrugs principle with lipid-based 
ormulations via the oral route could be a promising way to 
weak the pharmacokinetics of apomorphine. Additionally,
sing polymers to increase residence time in the nasal cav- 
ty or employing lipid-based formulations or iontophoresis for 
ransdermal application could be a way to achieve prolonged 
r measured systemic exposure to apomorphine. Sublingual 
elivery of apomorphine could be a better approach for avoid- 
ng hepatic first-pass metabolism and enabling rapid onset of 
ction. Hence, currently, it seems to be one of the most promis- 
ng non-invasive routes for delivery of apomorphine to PD pa- 
ients, also from the perspective of pharmaceutical industry. 
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